Moleculin Biotech (MBRX) Tax Provisions (2019 - 2020)
Moleculin Biotech (MBRX) posted quarterly Tax Provisions of -$229000.0 for Q3 2019.
Moleculin Biotech (MBRX) Tax Provisions (2019 - 2020) Analysis & Trends
Moleculin Biotech's Tax Provisions history runs 1 years deep, the most recent figure standing at -$229000.0 for Q3 2019.
- In Q3 2019, Tax Provisions changed N/A year-over-year to -$229000.0; the TTM figure through Dec 2020 stood at -$229000.0 (changed 0.0% YoY), while the FY2019 annual figure was -$229000.0, changed N/A from the prior year.
- Tax Provisions for Q3 2019 stood at -$229000.0.
- The five-year high for Tax Provisions was -$229000.0 in Q3 2019, with the low at -$229000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 3.65 Mn |
| Dec 31, 2019 | 3.00 Mn |
| Sep 30, 2019 | -229,000.00 |